NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
The gross proceeds to NeuroDerm were approximately $77 million. > Read More
NeuroDerm Ltd. Announces Pricing of Public Offering
NeuroDerm anticipates the total gross proceeds from the offering will be approximately $66.9 million.”> Read More
NeuroDerm Ltd. Files Registration Statement for Proposed Follow-On Offering
NeuroDerm Ltd. today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed public offering of its ordinary shares.
”> Read More